Omeros (OMER)
(Delayed Data from NSDQ)
$3.81 USD
-0.25 (-6.16%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $3.80 -0.01 (-0.26%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 181 - 200 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Omeros Corporation
Industry: Medical - Products
March and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Model Update to Include Debt Extinguishment Payment; Reiterate OUTPERFORM But Reducing PT to $62 for Error Correction.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Omeros Corporation
Industry: Medical - Products
Q3 Financials; Initial Omidria Launch Is Slower Than Expected but OMS721 Continues to Show Efficacy; Reiterate OUTPERFORM but Decreasing PT to $65.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
November and Remaining 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
September and 2015 Catalysts for Emerging PharmaceuticalsThis report contains brief updates on the following: BIOD, BMRN, CBYL, ICPT, LXRX, OMER, PCRX, RGLS, RLYP, SGMO, UTHR, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Emerging Pharmaceuticals: September and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Omeros Corporation
Industry: Medical - Products
OMS721 Achieves Clinical Proof-of-Concept for aHUS in Our View; Reiterate OUTPERFORM and Increasing Our Price Target to $70
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
We View Par''s Paragraph IV Filing As a Nuisance--Not a Threat; Reiterate OUTPERFORM and $61 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.